Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
30 results
  • Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. [Journal Article]
    Int J Cancer 2018; 142(2):369-380Van Sebille YZA, Gibson RJ, … Bowen JM
  • Dacomitinib, an irreversible small-molecule pan-ErbB TKI, has a high incidence of diarrhea, which has been suggested to be due to chloride secretory mechanisms. Based on this hypothesis, crofelemer, an antisecretory agent may be an effective intervention. T84 monolayers were treated with 1 µM dacomitinib and 10 µM crofelemer, and mounted into Ussing chambers for electrogenic ion analysis. Crofele…
  • HIV and diarrhoea: what is new? [Review]
    Curr Opin Infect Dis 2016; 29(5):486-94Logan C, Beadsworth MB, Beeching NJ
  • The review examines the changing causes and the investigation of infectious and noninfectious diarrhoea in individuals with HIV.
  • Drug discovery approaches to irritable bowel syndrome. [Review]
    Expert Opin Drug Discov 2015; 10(8):809-24Hornby PJ
  • CONCLUSIONS: Challenges for new drug discovery are the unknown mechanisms underlying IBS, making it difficult to predict clinically efficacious molecular targets, limited options for translational research and disease progression biomarkers. Drugs acting locally via multiple targets (e.g., eluxadoline [The U.S. Food and Drug Administration approved Viberzi (eluxadoline) for IBS-D on May 27th 2015], crofelemer) to validated mechanisms are proving successful with tolerable safety margins. Novel mechanisms, identified and optimized based on the emerging role of nutrient signaling, probiotics or microbial products, are promising. Therapeutic treatment earlier in disease progression may improve response and have longer term benefits.
New Search Next